Gelonghui, December 4 | According to a report published by Daiwa, the third-quarter results of Shiyao Pharmaceutical Group (1093.HK) are in line with expectations. Management mentioned that large-scale medical conferences began to restart in October. Due to the reduction in sales costs of some existing drugs, it is believed that the sales cost ratio will continue to improve. Management expects new products to bring in sales of more than 3 billion yuan next year, supporting the goal of achieving double-digit growth. The bank raised the company's target price from HK$6.5 to HK$7.6, mainly reflecting the bank's increase in sales forecasts for completed drugs and maintaining its outperforming market ratings.